Supplementary figure 1. ROS-low and ROS-high cells represent two distinct cell entities but both carry leukemia associated mutations (A) Experimental design to monitor cellular ROSstates over time under different culture conditions. (B) FACS plots indicating ROS levels of AML cells (sorted as in A) at the time of sort and after 3 or 6 days of culture in either serum-rich medium
Acute myeloid leukemia (AML) is a genetically heterogeneous disease characterized by the accumulation of immature myeloid blasts in the bone marrow. While conventional chemotherapy usually results in initial reduction of leukemic blasts in the majority of patients, disease relapse is frequent, especially in elderly patients. Disease relapse is likely driven by leukemia stem cells (LSCs) that are not affected by chemotherapy and therefore retain their disease-initiating properties. 1 Further characterization of this LSC population is therefore highly relevant.
In hematopoietic cells, the stage of differentiation and metabolic properties are closely linked. 2 Hematopoietic stem cells (HSCs) characteristically have low levels of mitochondrial oxidative metabolism and consequently low levels of reactive oxygen species (ROS), which is relevant for their function. 3, 4 A similar concept seems to apply for leukemic cells: Within the total mononuclear AML cell population (AML-MNCs), LSCs were shown to predominantly reside in the cell fraction with relatively low levels of ROS. 5, 6 While previous studies highlighted that LSCs have lower ROS levels compared to the remaining mononuclear AML cells, 5 the present study investigates how distinct ROS levels within the stemcell-enriched CD34 + AML cell fraction correlate with cellular characteristics like morphology, gene expression, metabolic activity and drug responsiveness. We found that CD34 + AML cells with low ROS levels are smaller, have a significantly increased expression of genes associated with stemness (such as ABCB1, MEIS1, CD109) and negative regulation of signaling (such as SPRY1, DUSP10, PIK3IP1), and show an increased sensitivity to the BCL2 inhibitor Venetoclax, which was not linked to an increased expression of BCL2, but might be related to an increased expression of the MCL1 regulator NOXA 7 and the BCL2L1 repressor ATF3. 8 We compared morphological characteristics of CD34 + AML cells with low or high ROS levels, which were defined as cell fractions with the 15% lowest and 15% highest signal intensity for a fluorescence-based ROS dye ( Figure 1A) . Among AML patients with various genetic backgrounds, ROS-low CD34 + cells were consistently smaller compared to their ROS-high counterparts (Figure 1 B-C ). ROS-low and ROS-high sorted AML CD34 + cells maintained a distinctive ROS-state for up to one week in culture ( Supplementary figure 1 A-B ), indicating that ROS levels in CD34 + AML cells do not fluctuate highly and that cell sorting based on ROS levels separates two distinct cell entities. Notably, we confirmed the presence of leukemia-associated mutations in both the ROS-low and ROS-high fraction. In some samples, the co-mutational pattern was different between the two fractions, likely reflecting different leukemic subclones (Supplementary figure 1 C-D and supplementary table S1).
RNA sequencing was used to gain insight into transcriptional differences between ROS-low and ROS-high CD34 + AML cells (n=4). Due to high biological variance, principal component analysis (PCA) showed that samples cluster based on patient samples and not on ROS levels (Supplementary figure 2A) . Differential expression analysis identified 58 commonly up-regulated and 148 commonly down-regulated high confidence genes in the ROS-low AML CD34 + cell fraction compared to ROS-high AML CD34 + cells ( Figure 1D, supplementary figure 2 B-C). Gene ontology (GO) analysis revealed that genes upregulated in the ROS-low fraction were associated with negative regulation of signaling, whereas down-regulated genes were associated with increased cell differentiation ( Figure 1E ). Validation of RNA-seq data by RT-qPCR in additional AMLs (n=8) demonstrated that ROS-low CD34 + AML cells have significantly increased expression of stemness-associated genes (ABCB1, MEIS1, CD109, GFI1B), genes related to negative regulation of signaling (SPRY1, DUSP10, PIK3IP1, DDIT4) and apoptosis (NOXA, ATF3) ( Figure 1F, supplementary figure 3 ). High expression of the drug-efflux transporter ABCB1 is associated with therapy resistance and poor prognosis in AML, 9 and functional validation of ABCB1 activity by transporter activity assays showed almost exclusive activity in the ROS-low CD34 + AML cells ( Figure 1G, supplementary figure 4 ). In line with the increased expression of genes related to stemness, we observed an increased percentage of CD34 + CD38cells in the ROS-low fraction ( Figure 1H) .
Notably, the observed transcriptional differences between ROS-low and ROS-high CD34 + cells were not AML-specific, since increased expression of most of these genes could also be found in the ROS-low fraction of normal CD34 + cells isolated from cord blood (CB) or mobilized Even though ROS production is strongly correlated with mitochondrial activity, 2 our RNA-seq data didn't show differentially expressed genes related to mitochondrial energy metabolism in ROS-low vs. ROS-high CD34 + AML cells. Analysis of mitochondrial characteristics by electron microscopy revealed fewer mitochondrial structures in ROS-low CD34 + AML cells (Figure 2 A-B), which was in line with a lower mitochondrial DNA copy number ( Figure 2C ). However, ROSlow CD34 + AML cells had a smaller cytoplasm area ( Figure 2D ), and the ratio calculated from cytoplasm area and number of mitochondria was similar in both fractions ( Figure 2E ). This suggests that ROS-low cells contain a lower absolute number of mitochondria compared to ROS-high cells, but their mitochondrial content relative to their cell size is the same. Consistent with that, we observed comparable TOM20 protein expression in both fractions when the signal was normalized to β-ACTIN ( Figure 2F ). ROS-low AML CD34 + cells had significantly lower amounts of ATP ( Figure 2G ) and the fluorescence probe TMRM (tetramethylrhodamine) indicated lower levels of mitochondrial membrane potential (MMP) in this fraction ( Figure 2H ). To exclude that ROS-low and ROS-high cells might metabolize fluorescence dyes differentially, MMP was also measured using Rhodamine 123 in the presence of cyclosporine A, which blocks drug efflux transporters. These measurements yielded similar results ( Figure 2I ).
It has been shown that ROS-low AML cells from the MNC fraction are more sensitive to inhibition of the anti-apoptotic mitochondrial regulator BCL2 compared to ROS-high cells, which was linked to increased BCL2 expression at both RNA-and protein level. 5 Furthermore, combination of the BCL2 inhibitor Venetoclax and azacitidine was shown to target LSCs in AML patients. 10 Notably, our RNA-seq data did not reveal increased BCL2 expression in ROS-low CD34 + AML cells compared to ROS-high CD34 + AML cells, nor did we observe a consistent overexpression of BCL2 protein ( Figure 3A ). Despite this, we observed that the ROS-low CD34 + AML cells were significantly more sensitive to Venetoclax treatment compared to their ROS-high counterparts ( Figure 3B, supplementary figure 6A ), whereby ROS-low CD38 + and CD38cells were equally efficiently targeted (Supplementary figure 6B ). This seems to be Venetoclax specific, since treatment of ROS-low and ROS-high CD34 + AML cells with the MCL1 inhibitor S63845 only mildly affected the viability of both cell fractions ( Figure 3C ). While combined treatment with both Venetoclax and S63845 had no additional effect on the AML CD34 + ROSlow fraction, it eventually also eliminated ROS-high cells in a dose-dependent manner ( Figure   3D ). This supports the notion that the anti-apoptotic proteins BCL2 and MCL1 are both involved in regulating AML cell survival, 11 but demonstrates that ROS-low cells have an increased BCL2 dependency. Considering the role of BCL2 as a mitochondrial regulator, we wondered if ROS-low cells are generally more sensitive to a direct block of mitochondrial activity. However, treatment of ROS-low and ROS-high CD34 + AML cells with the mitochondrial uncoupler FCCP targeted both cell fractions (Supplementary figure 7) .
In summary, our data highlight that CD34 + AML cells with low ROS levels are smaller, have stemness-related features and thereby most likely coincide with the LSC population. ROS-low CD34 + AML cells showed increased expression of genes previously linked to stress-and drugresistance and poor prognosis in AML patients (e.g. CD109 12 , MEIS1 13 , ABCB1 9 ), highlighting that targeting this population is crucial for successful AML therapy. We show that ROS-low AML CD34 + cells are highly sensitive to BCL2 inhibition by Venetoclax, which could not be explained by higher BCL2 expression in this fraction, but potentially is related to increased expression of additional apoptosis regulators such as NOXA or ATF3, which are involved in inactivation of the anti-apoptotic proteins MCL1 and BCL2L1, respectively. 7, 8 Notably, MCL1 expression was shown to inversely correlate with sensitivity to BCL2 inhibition in AML, 14 whereas recently impaired ATF3 expression was associated with resistance to the combination of Venetoclax and ibrutinib in mantel cell lymphoma. 15 
Figure legends

Supplementary figure 2. ROS-low CD34 + AML cells show increased expression of genes that negatively regulated cell-proliferation and differentiation (A)
Table S1. Characteristics of AML patient samples used in the present study
Clinical characteristics of the studied AML samples. If sequencing data was available, identified mutations and the variant allele frequency are indicated. All material was obtained from newly diagnosed AML patients. AML: acute myeloid leukemia; N.D: not determined.
Material and Methods
Normal Hematopoietic cells and AML patient material
Umbilical cord blood (CB) was derived from healthy full-term pregnancies after informed consent 
Preparation of primary material for subsequent analysis
Frozen material was defrosted one day prior to further analysis. CB cells were cultured overnight 
Cell separation based on ROS levels
Normal -or leukemic CD34 + cells, prepared as described above, were resuspended in PBS/3%FCS/Fc-block and stained with 5 µM CellROX Deep Red reagent (Life Technologies) and
antibodies for CD34/CD38 selection (CD34-PE, CD38-FITC, both BD Biosciences) for 30 min at 37 °C. Afterwards, cells were washed with PBS/3%FCS and resuspended in PBS/3%FCS containing 10 µM DAPI. Labelled cells were further analyzed using LSR II (BD Biosciences) and were scored as positive. LTC-IC frequency was calculated using the L-Calc software.
Immunoblotting
Preparation of cell lysates and immunoblotting procedure was performed as described previously. 2 Primary antibodies for immunoblotting were: BCL2 (2872, Cell Signaling), TOM20 (D8T4N, 42406, Cell Signaling), HDAC1 (10E2, 5356, Cell Signaling), β-ACTIN (C4, SC-47778, Santa Cruz).
ABCB1 transporter activity assay
Sorted CD34 + AML cells were divided in two tubes and resuspended in either 1 ml of αMEM or in In brief: 25ng -1ug input RNA was depleted from ribosomal RNA by oligo hybridization, RNaseH treatment and DNase digestion. rRNA-depleted RNA was fragmented to ~200 bp fragments and first strand synthesis was performed using random primers. The second-strand was synthesized using dUTP for strand specificity. After adapter ligation, library amplification was performed and the number of cycles was dependent on the amount of starting material. A bioanalyser with a high sensitivity DNA Chip (Agilent) was used to check fragment size. Samples were sequenced on an Illumina NextSeq 500 system with 2×43 bp paired-end sequencing (PE43).
RNA-Sequencing analysis
STAR aligner with UCSC gene annotation first indexed the hg19 reference genome. The resulting RNA-seq reads were mapped to the hg19 genome using STAR with two-pass mode, and the gene-level read counts were enumerated at the same time. EdgeR (v3.24.3) was used to examine differentially expressed genes and genes with ≥1log difference and adj p-value of <0.01 were considered significant. EdgeR analysis was overlapped with genes that have > 1.5 fold difference in all samples in a pairwise comparison. Raw RNA-Sequencing data are available at http://www.ncbi.nlm.nih.gov/geo, with accession code: GSE131422. GO-analysis was performed with metascape (www.metascape.org).
Mitochondrial copy number assay
Total DNA was isolated from >1 x10 5 cells using QIAamp DNA mini kit (Qiagen). DNA was amplified real-time in SYBR Green Supermix (Bio-Rad) using the CFX connect Thermocycler (Bio-Rad). Nuclear genes (GAPDH and B2M) and mitochondrial genes (12S and tRNA) were amplified using the following primers:
The obtained CT values were corrected for the corresponding calculated primer reaction efficiencies. Based on the corrected CT values, the mitochondrial DNA copy number was calculated relative to nuclear DNA copy number. 4
ATP assay
Luminescent ATP detection Assay kit (Abcam, ab113849) was used according to the manufactures protocol to measure levels of ATP. ATP levels were measured using a Bio-Rad benchmark III Bio-Rad microtiter spectrophotometer. 
Mutational analysis and targeted sequencing
Presence of the FLT-ITD mutation was analyzed by PCR using following primers: FLT3-ITD_fw:
CGGCACAGCCCAGTAAAGATA; FLT3-ITD_rev: GCCCAAGGACAGATGTGATG; The NPM1 region was amplified using following primers: NPM1_W288fs_fw: TCGGGAGATGAAGTTGGAAG and NPM1_W288fs_rev: ACGGTAGGGAAAGTTCTCAC, and presence of the mutation was verified by Sanger-Sequencing (Eurofins).
Ultrastructural analysis
The experimental procedure for ultrastructural analysis of hematopoietic cells has been described previously. 5 In brief, 1-2 million ROS-low and ROS-high sorted CD34 + AML cells were pelleted and subsequently fixed in 2% paraformaldehyde and 2% glutaraldehyde in 0.1M cacodyladate buffer for 24h at 4 °C. After fixation, the cells were washed in in 0.1M cacodyladate buffer. Cells were stained with Evans blue and subsequently embedded in low melting point agarose as described previously. 6 Agarose pieces containing the cell pellet were dehydrated, osmicated, and embedded in Epon according to routine procedures. Semi-thin sections (0.5mm) stained with toluidine blue were inspected using light microscopy to identify the position of cells. Ultra-thin sections (60-80 nm) were cut and stained with 4% uranyl acetate in water, followed by Reynolds lead citrate. Images were taken with the FEI/Philips CM100 (Eindhoven, the Netherlands).
Measurement mitochondrial structures and cytoplasm area
Electron microscopy images of ROS-low and ROS-high sorted CD34 + AML cells were taken as described above. On these images, mitochondrial structures were counted from 25-70 cells per sample. Similar, the cytoplasm area of 25-70 cells per sample was outlined and measured using ImageJ. To report the relation between cell size and mitochondrial content, the ratio of the average cytoplasm area and the average number of mitochondrial structures per sample was calculated.
Analysis of cell viability after drug treatment
ROS-low and ROS-high CD34 + AML cells were sorted as described above and resuspended in 
